APA (7th ed.) Citation

Dodick, D. W., Lipton, R. B., Ailani, J., Halker Singh, R. B., Shewale, A. R., Zhao, S., . . . Viswanathan, H. N. (2020). Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II. Headache: The Journal of Head & Face Pain, 60(4), 686. https://doi.org/10.1111/head.13766

Chicago Style (17th ed.) Citation

Dodick, David W., Richard B. Lipton, Jessica Ailani, Rashmi B. Halker Singh, Anand R. Shewale, Sihui Zhao, Joel M. Trugman, Sung Yun Yu, and Hema N. Viswanathan. "Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II." Headache: The Journal of Head & Face Pain 60, no. 4 (2020): 686. https://doi.org/10.1111/head.13766.

MLA (9th ed.) Citation

Dodick, David W., et al. "Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II." Headache: The Journal of Head & Face Pain, vol. 60, no. 4, 2020, p. 686, https://doi.org/10.1111/head.13766.